Prosecution Insights
Last updated: April 19, 2026
Application No. 17/284,947

Softgels with solid or gel-like polymeric fill matrix

Non-Final OA §112
Filed
Apr 13, 2021
Examiner
TCHERKASSKAYA, OLGA V
Art Unit
1615
Tech Center
1600 — Biotechnology & Organic Chemistry
Assignee
BAYER AKTIENGESELLSCHAFT
OA Round
5 (Non-Final)
55%
Grant Probability
Moderate
5-6
OA Rounds
2y 9m
To Grant
99%
With Interview

Examiner Intelligence

Grants 55% of resolved cases
55%
Career Allow Rate
453 granted / 820 resolved
-4.8% vs TC avg
Strong +47% interview lift
Without
With
+47.2%
Interview Lift
resolved cases with interview
Typical timeline
2y 9m
Avg Prosecution
67 currently pending
Career history
887
Total Applications
across all art units

Statute-Specific Performance

§101
0.7%
-39.3% vs TC avg
§103
36.3%
-3.7% vs TC avg
§102
7.9%
-32.1% vs TC avg
§112
35.1%
-4.9% vs TC avg
Black line = Tech Center average estimate • Based on career data from 820 resolved cases

Office Action

§112
DETAILED ACTION Continued Examination Under 37 CFR 1.114 A request for continued examination under 37 CFR 1.114, including the fee set forth in 37 CFR 1.17(e), was filed in this application after final rejection. Since this application is eligible for continued examination under 37 CFR 1.114, and the fee set forth in 37 CFR 1.17(e) has been timely paid, the finality of the previous Office action has been withdrawn pursuant to 37 CFR 1.114. Applicant's submission, filed 01/20/2026, has been entered. Status of Application Receipt of the amendments to the claims and applicant arguments/remarks, filed 01/20/2026, is acknowledged. Applicant has previously elected without traverse the invention of Group I, claims 1-18, 37 drawn to a composition comprising a fluid fill mass comprising an active ingredient(s), a polymerizable monomer(s), a polymerization initiator(s). Claims 1, 4, 7, 9, 11, 13-16, 19-43 are pending in this application. Claims 19-36, 38-40 have been withdrawn from further consideration pursuant to 37 CFR 1.142(b) as being drawn to a nonelected species and inventions, there being no allowable generic or linking claim. Claims 2-3, 5-6, 8, 10, 12, 17-18 have been cancelled previously. Claims 1, 37 have been amended. New claims 41-43 have been added. No new matter was added. Claims 1, 4, 7, 9, 11, 13-16, 37, 41-43 are currently under consideration. Any rejection or objection not reiterated in this action is withdrawn. Applicant's amendments necessitated new ground(s) of rejection presented in this office action. The present application, filed on or after March 16, 2013, is being examined under the first inventor to file provisions of the AIA . Priority This application is a 371 of PCT/US2019/056481, filed October 16, 2019, which claims benefit of provisional U.S. Application No. 62/915,231, filed October 15, 2019, and U.S. Application No. 62/746,184, filed October 16, 2018. Claim Objections Claim 37 is objected to because of the following informalities: As stated previously, claim 37 comprises the typographic error “in an amount less than” that needs to be corrected to “in an amount of less than”. Appropriate correction is required. Claim Rejections - 35 USC § 112(b) The following is a quotation of 35 U.S.C. 112(b): (b) CONCLUSION.—The specification shall conclude with one or more claims particularly pointing out and distinctly claiming the subject matter which the inventor or a joint inventor regards as the invention. The following is a quotation of 35 U.S.C. 112 (pre-AIA ), second paragraph: The specification shall conclude with one or more claims particularly pointing out and distinctly claiming the subject matter which the applicant regards as his invention. Claims 1, 4, 7, 9, 11, 13-16, 37, 41-43 are rejected under 35 U.S.C. 112(b) or 35 U.S.C. 112 (pre-AIA ), second paragraph, as being indefinite for failing to particularly point out and distinctly claim the subject matter which the inventor or a joint inventor, or for pre-AIA the applicant regards as the invention. Newly amended claim 1 recites the limitations “at least one solvent” and “the solvent is polyethylene glycol” that is not reasonably clear. First, it is unclear what solvent should be used in the claimed compositions – a mixture (i.e., “at least one”), or polyethylene glycol (PEG). Second, it is noted that the instant specification teaches the use of PEG as a polymer in a fluid mass (Page 8), low molecular PEG as a solvent constituent (Page 12), and/or PEG as an optional excipient (Page 17). Therefore, the scope of the claim is not reasonably clear. Similar is applied to claim 13, as well as to claims 14-15 regarding the use of PEG and ethanol, and to claim 37 regarding the use of PEG with ethanol and water. Clarification is required. New claim 41 recites the limitation “polymerizable monomer comprises a mixture of methacrylic acid and a salt of methacrylic acid” that is not reasonably clear, because the molecule/monomer is defined as a mixture (i.e., comprising). Clarification is required. New claim 43 recites the term "about” that is a relative term, which renders the claim indefinite. This term is not defined by the claim, the specification does not provide a standard for ascertaining the requisite degree, and one of ordinary skill in the art would not be reasonably apprised of the scope of the invention. Clarification is required. New claim 43 recites the limitation “composition releases at least 80% of the active ingredient” that is unclear and indefinite, given that said numerical limitation is shown with and without units of measurements. Therefore, the metes and bounds of the claim are not reasonably clear. Clarification is required. Claims 4, 7, 9, 11, 16, 42 are rejected as being dependent on rejected independent claim 1 and failing to cure the defect. Response to Arguments Applicant's arguments, filed 01/20/2026, have been fully considered, and they were found to be persuasive. The 103-rejection of record has been withdrawn. The prior art does not teach a fluid fill mass composition comprising constituents/compounds as instantly claimed that does not comprise/include a cross-linking agent, and wherein activation of a polymerization initiator leads to production of a polymeric fill matrix in a form of a solid or gel-like polymeric fill that entraps active ingredients in a reversible polymer matrix, i.e., in a matrix that is in a collapse state at acidic pH (e.g., in stomach) preventing disintegration/dissolution of the filler in this medium, and wherein said matrix can dissolve/disintegrate in the gastrointestinal tract (e.g., at pH 6.8). Applicant is advised to clarify the compounds to be included into the claimed composition/product, the structure of the claimed compositions and clearly point out the patentable novelty, which the applicant thinks the claims present in view of the state of the art, to place the application in condition for allowance. Conclusion Claims 1, 4, 7, 9, 11, 13-16, 37, 41-43 are rejected, but would be allowable if rewritten or amended to overcome the rejection(s) under 35 U.S.C. 112(b) or 35 U.S.C. 112 (pre-AIA ), 2nd paragraph, set forth in this Office action. Regarding withdrawn claims 19-36, 38-40 nonelected without traverse (see Office Action, filed 11/13/2023), the applicant is advised to cancel or amend the withdrawn claims to clarify the special technical feature for rejoinder. MPEP 821. 04. Correspondence Any inquiry concerning this communication or earlier communications from the examiner should be directed to OLGA V. TCHERKASSKAYA whose telephone number is (571)270-3672. The examiner can normally be reached 9 am - 6 pm, Monday - Friday. Examiner interviews are available via telephone, in-person, and video conferencing using a USPTO supplied web-based collaboration tool. To schedule an interview, applicant is encouraged to use the USPTO Automated Interview Request (AIR) at http://www.uspto.gov/interviewpractice. If attempts to reach the examiner by telephone are unsuccessful, the examiner’s supervisor, Robert A. Wax can be reached on (571) 272-0623. The fax phone number for the organization where this application or proceeding is assigned is 571-273-8300. Information regarding the status of published or unpublished applications may be obtained from Patent Center. Unpublished application information in Patent Center is available to registered users. To file and manage patent submissions in Patent Center, visit: https://patentcenter.uspto.gov. Visit https://www.uspto.gov/patents/apply/patent-center for more information about Patent Center and https://www.uspto.gov/patents/docx for information about filing in DOCX format. For additional questions, contact the Electronic Business Center (EBC) at 866-217-9197 (toll-free). If you would like assistance from a USPTO Customer Service Representative, call 800-786-9199 (IN USA OR CANADA) or 571-272-1000. /OLGA V. TCHERKASSKAYA/ Examiner, Art Unit 1615 /Robert A Wax/Supervisory Patent Examiner, Art Unit 1615
Read full office action

Prosecution Timeline

Apr 13, 2021
Application Filed
Mar 04, 2024
Non-Final Rejection — §112
Jul 15, 2024
Response Filed
Oct 13, 2024
Final Rejection — §112
Mar 21, 2025
Request for Continued Examination
Mar 24, 2025
Response after Non-Final Action
Apr 23, 2025
Non-Final Rejection — §112
Jul 28, 2025
Response Filed
Oct 12, 2025
Final Rejection — §112
Jan 20, 2026
Request for Continued Examination
Jan 26, 2026
Response after Non-Final Action
Mar 18, 2026
Non-Final Rejection — §112 (current)

Precedent Cases

Applications granted by this same examiner with similar technology

Patent 12594243
PHARMACEUTICAL FORMULATIONS
2y 5m to grant Granted Apr 07, 2026
Patent 12576026
FORMULATIONS OF NEBIVOLOL
2y 5m to grant Granted Mar 17, 2026
Patent 12568971
DEGRADATIVE METHOD
2y 5m to grant Granted Mar 10, 2026
Patent 12569434
FORMULATIONS OF NEBIVOLOL
2y 5m to grant Granted Mar 10, 2026
Patent 12564585
Nutraceuticals Having Sustained Release for Improved Bioavailability and Method of Production
2y 5m to grant Granted Mar 03, 2026
Study what changed to get past this examiner. Based on 5 most recent grants.

AI Strategy Recommendation

Get an AI-powered prosecution strategy using examiner precedents, rejection analysis, and claim mapping.
Powered by AI — typically takes 5-10 seconds

Prosecution Projections

5-6
Expected OA Rounds
55%
Grant Probability
99%
With Interview (+47.2%)
2y 9m
Median Time to Grant
High
PTA Risk
Based on 820 resolved cases by this examiner. Grant probability derived from career allow rate.

Sign in with your work email

Enter your email to receive a magic link. No password needed.

Personal email addresses (Gmail, Yahoo, etc.) are not accepted.

Free tier: 3 strategy analyses per month